Brown Advisory Inc. Lowers Stock Holdings in Medtronic PLC $MDT

Brown Advisory Inc. lessened its holdings in shares of Medtronic PLC (NYSE:MDT) by 3.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 272,432 shares of the medical technology company’s stock after selling 10,512 shares during the quarter. Brown Advisory Inc.’s holdings in Medtronic were worth $23,748,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in MDT. 1248 Management LLC acquired a new position in Medtronic in the first quarter valued at $26,000. Twin Tree Management LP purchased a new stake in Medtronic in the 1st quarter valued at about $29,000. Activest Wealth Management increased its stake in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares during the last quarter. GFG Capital LLC acquired a new position in shares of Medtronic during the 2nd quarter valued at about $36,000. Finally, True Wealth Design LLC lifted its holdings in shares of Medtronic by 49.8% during the 2nd quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock worth $37,000 after acquiring an additional 140 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Royal Bank Of Canada boosted their target price on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Stifel Nicolaus boosted their price objective on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Jefferies Financial Group restated a “hold” rating and set a $110.00 price objective on shares of Medtronic in a report on Wednesday, November 19th. Finally, Argus lifted their target price on Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and a consensus price target of $110.44.

Medtronic Stock Performance

Shares of MDT stock opened at $101.39 on Friday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The company has a market cap of $129.99 billion, a PE ratio of 27.33, a P/E/G ratio of 2.67 and a beta of 0.71. The company’s fifty day simple moving average is $96.79 and its 200-day simple moving average is $92.22. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the prior year, the company earned $1.26 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.